Topics

Teplizumab delays type 1 diabetes diagnosis in high risk patients

10:00 EDT 15 Aug 2019 | 2 Minute Medicine

1. In relatives of patients with type 1 diabetes (T1DM) at risk for disease development, randomization to teplizumab delayed time to T1DM diagnosis compared to placebo treated patients. 2. Adverse events associated with teplizumab treatment included rash and transient lymphopenia. Evidence Rating Level: 1 (Excellent)   Study Rundown: T1DM results from autoimmune destruction of insulin-producing […]
Source: 2 Minute Medicine

Original Article: Teplizumab delays type 1 diabetes diagnosis in high risk patients

NEXT ARTICLE

More From BioPortfolio on "Teplizumab delays type 1 diabetes diagnosis in high risk patients"

Quick Search

Relevant Topic

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...